Related coverage linked through entity extraction aliases.
Aug 25, 2026
Researchers at Monash University and the University of Southern California have developed kidney organoids from stem cells to study acute kidney injury and kidney development. Additionally, Auxilium Biotechnologies 3D-printed living kidney and liver tissue aboard the International Space Station for the first time.
Jun 02, 2026
Gene editing repaired a Dravet syndrome mutation in mice, a prenatal hemophilia A therapy showed maternal safety in sheep, and researchers advanced toward a genetic test for valproic acid use in pregnancy.
May 26, 2026
The global radiopharmaceuticals market is projected to reach $12.8B–$21.8B by 2033–2036, driven by cancer therapy demand. Oncology accounts for over 50% of applications, Technetium-99m dominates radioisotopes, and Asia-Pacific leads growth.
Mar 23, 2026
Monash University and Ono Pharmaceutical have signed two licence agreements for the development of anti-GPCR antibodies targeting autoimmune and inflammatory diseases. The agreements result from Ono exercising options on research collaborations announced in 2023. The partnership combines Monash's research excellence with Ono's drug development capabilities to address unmet medical needs.
Feb 18, 2026
Researchers have identified how the MYC protein helps pancreatic cancer evade immune detection, while a separate team discovered methods to permanently switch off cancer genes in leukemia through epigenetic therapy targeting Menin and DOT1L proteins.
Feb 16, 2026
Researchers at Monash University have identified DNA sequence variations in mothers that modify the risk of birth defects from valproic acid, an anti-seizure medication, paving the way for a genetic test to identify who can safely take the drug during pregnancy.
